This is a paid press release. Contact the press release distributor directly with any inquiries.
Aptevo Provides 2Q26 Business Update and Reports Second Quarter <a href="https://bitcomme.com/tuhura-biosciences-reports-second-quarter-2026-financial-results-and-provides-a-corporate-update/” title=”TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update”>Financial Results
Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2
Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline
Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy
Strategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity
SEATTLE, WA /ACCESS Newswire/ August 14, 2026 /Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2026 and provided a business update highlighting strong clinical progress for mipletamig, strengthened scientific leadership, non-dilutive funding to advance its solid tumor trispecific pipeline and expansion into radiopharmaceutical therapeutic development through a 50/50 collaboration with Niowave.
“During the second quarter, we made important progress against the programs and initiatives we believe can create near- and long-term value for Aptevo,” said Jeff Lamothe, President and Chief Executive Officer of Aptevo. “Mipletamig continues to lead our value creation strategy, with RAINIER generating compelling frontline acute myeloid leukemia data and moving toward completion of dose optimization by year end and Phase 2 regulatory interaction early in 2027. We also strengthened our scientific leadership, secured non-dilutive funding to advance trispecific candidate APVO451, and entered a 50/50 collaboration with Niowave that gives us a cost-effective path into radiopharmaceutical therapeutics and access to isotope supply in a constrained market. Together, these achievements put us in a stronger position to advance our pipeline and pursue multiple opportunities to create shareholder value.”
Mipletamig remained Aptevo’s most advanced and central value driver during the quarter, with updated Phase 1b/2 RAINIER trial data continuing to show strong clinical activity in frontline acute myeloid leukemia (AML) when combined with venetoclax and azacitidine. Across 31 evaluable unfit frontline AML patients (through Cohort 5 plus four frontline patients from the completed dose expansion trial), mipletamig demonstrated an 87% clinical benefit rate and an 81% remission rate, supporting its potential to improve standard-of-care outcomes for a patient population with significant unmet need. Safety data observed to date demonstrate mipletamig’s combinability, safety and tolerability in combination with standard-of-care therapy. RAINIER has entered the final stage of dose optimization, positioning Aptevo to complete the Phase 1b RAINIER trial and select the recommended Phase 2 dose this year in anticipation of a Phase 2 regulatory interaction in 1Q27.
